Madrigal Pharmaceuticals, Inc.
(NASDAQ : SNTA)

( )
SNTA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Loading SNTA News...
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
2.03%17.6014.2%$409.51m
SHPGShire PLC Sponsored ADR
-1.58%160.220.4%$218.00m
PRXLPAREXEL International Corporation
-0.03%87.367.9%$106.01m
PTLAPortola Pharmaceuticals, Inc.
0.48%65.298.9%$104.05m
MNKMallinckrodt Plc
4.06%46.6917.7%$93.51m
PRGOPerrigo Co. Plc
3.92%75.506.4%$87.48m
JAZZJazz Pharmaceuticals Plc
2.38%159.852.2%$69.43m
UTHRUnited Therapeutics Corporation
0.08%131.3613.9%$67.14m
ALRAlere Inc.
0.03%50.402.7%$64.80m
ENDPEndo International Plc
1.99%12.328.9%$51.53m
CTLTCatalent Inc
-0.61%35.852.8%$43.79m
HZNPHorizon Pharma plc
-0.77%12.917.6%$43.55m
ICPTIntercept Pharmaceuticals, Inc.
1.74%128.6622.1%$43.21m
MDCOMedicines Company
3.88%39.0822.3%$35.83m
SAGESAGE Therapeutics, Inc.
0.54%81.4111.9%$32.32m

Company Profile

Madrigal Pharmaceuticals, Inc. clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel compounds for the treatment of cardiovascular, metabolic and liver diseases. The company offers MGL-3196, an orally administered, small-molecule liver-directed ß-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Madrigal Pharmaceuticals was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.